Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab

被引：6

作者：

Dallari, Simone ^{[1
]}

Franciotta, Diego ^{[2
]}

Carluccio, Silvia ^{[1
]}

Signorini, Lucia ^{[1
]}

Gastaldi, Matteo ^{[2
]}

Colombo, Elena ^{[2
]}

Bergamaschi, Roberto ^{[2
]}

Elia, Francesca ^{[1
]}

Villani, Sonia ^{[1
]}

Ferrante, Pasquale ^{[1
,3
]}

Delbue, Serena ^{[1
]}

机构：

[1] Univ Milan, Dept Biomed Surg & Dent Sci, I-20133 Milan, Italy

[2] Natl Neurol Inst C Mondino, Dept Gen Neurol, Pavia, Italy

[3] Hlth Sci Fdn, Fdn Ettore Sansavini, Lugo, Italy

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2015年 / 287卷

关键词：

Multiple sclerosis; Natalizumab; Monocytes; ANTIBODY NATALIZUMAB; CELLS; MECHANISMS; BIOMARKER; RISK;

D O I：

10.1016/j.jneuroim.2015.08.010

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Natalizumab is a humanized monoclonal antibody against the alpha 4 subunit of VLA-4 integrin that is used to treat conditions such as multiple sclerosis (MS). Although its effects on lymphocytes have been widely described, little is known about its effects on monocytes. Here we described the effects of natalizumab treatment on peripheral blood monocytes from a small cohort of MS patients in terms of relative frequencies and surface integrin (CD49d and CD18) expression. We showed that natalizumab treatment altered the surface integrin expression on monocyte subsets in the peripheral compartment, suggesting a role for them as mediators of natalizumab effects. (C) 2015 Elsevier B.V. All rights reserved.

引用

页码：76 / 79

页数：4

共 50 条

[31] Natalizumab and risk of melanoma: a prospective follow-up of patients treated by natalizumab for multiple sclerosis
Castela, E.
Lebrun, C.
Rocher, F.
Cohen, M.
Passeron, T.
MULTIPLE SCLEROSIS, 2009, 15 (09): : S231 - S231
[32] Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
Heesen, Christoph
Kleiter, Ingo
Nguyen, Franziska
Schaeffler, Nina
Kasper, Juergen
Koepke, Sascha
Gaissmaier, Wolfgang
MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (12) : 1507 - 1512
[33] Morphea in a Multiple Sclerosis Patient Treated with Natalizumab
Alikhani, Katayoun
Kremenchutzky, Marcelo
NEUROLOGY, 2010, 74 (09) : A418 - A419
[34] Study of the JC virus presence in multiple sclerosis patients treated with natalizumab
Dominguez-Mozo, M. I.
Garcia-Montojo, M.
De las Heras, V.
Garcia-Martinez, M. A.
Arias-Leal, A.
Casanova, I.
Alvarez-Lafuente, R.
Arroyo, R.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 370 - 371
[35] Proposed MRI Safety Monitoring of Patients with Multiple Sclerosis Treated with Natalizumab
Vaneckova, M.
Seidl, Z.
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2016, 79 (06) : 663 - 669
[36] Systematic Assessment of JC Virus in Multiple Sclerosis Patients Treated with Natalizumab
Slesari, Iuliana
Heinzlef, Olivier
Poveda, Jean-Dominique
NEUROLOGY, 2010, 74 (09) : A369 - A369
[37] Systematic assessment of JC virus in multiple sclerosis patients treated with natalizumab
Slesari, I.
Heinzlef, O.
Poveda, J. -D.
JOURNAL OF NEUROLOGY, 2010, 257 : S220 - S220
[38] More on JC Viremia in Natalizumab-Treated Patients with Multiple Sclerosis
Subramanyam, Meena
Belachew, Shibeshih
Compton, Teresa
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (13): : 1279 - 1280
[39] JC virus DNA detection in multiple sclerosis patients treated with natalizumab
Dominguez-Mozo, M. I.
Garcia-Montojo, M.
De las Heras, V.
Garcia-Martinez, M. A.
Arias-Leal, A. M.
Casanova, I.
Alvarez-Lafuente, R.
Rooyo, R.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S357 - S358
[40] Systemic assessment of JC virus in multiple sclerosis patients treated with natalizumab
Slesari, I.
Manzouni, T.
Brugeilles, H.
Romatet, S.
Chamouard, J.
Poveda, J. D.
Heinzlef, O.
MULTIPLE SCLEROSIS, 2009, 15 (09): : S120 - S120

← 1 2 3 4 5 →